Clinical trials: Nonalcoholic Steatohepatitis
Metabolic Associated Fatty Liver Disease
Benefits of Trimetazidine in MASLD Patients
Objective of this study is to determine the clinical benefits of trimetazidine in improvement of MASLD
- Trial name
- MASLD (NCT06140953)
- Testing
- Trimetazidine, Conventional therapy
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- October 6 University
Metabolic Associated Fatty Liver Disease
Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study
The goal of this single arm, prospective study is to test the therapeutic response of oral dapagliflozin (Forxiga) 10 mg/day for 24 weeks in non-diabetic MAFLD patients.
- Trial name
- NCT05782972
- Testing
- dapagliflozin (Forxiga)
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome
The goal of this clinical trial is to investigate the use of ultra-high performance liquid chromatography-mass spectrometry for metabolomics and proteomics research in patients with Polycystic Ovary Syndrome (PCOS) and…
- Trial name
- NCT06256289
- Testing
- Canagliflozin 100mg Tab, Metformin Hydrochloride
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ping Li,MD
Healthy
Study to Estimate How Common it is to Have Genetic Variants Associated With NAFLD
The purpose of this study is to estimate the prevalence of genetic variants associated with liver disease in participants who are known, or are likely to have NAFLD.
- Trial name
- NCT04494360
- Testing
- No intervention
- Where
- 3 sites in United States
- Volunteers
- 830 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
HIV Infections, Non-Alcoholic Fatty Liver Disease
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
The purpose of this study was to evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.
- Trial name
- NCT04216589
- Testing
- Semaglutide
- Where
- 9 sites in United States, Brazil
- Volunteers
- 51 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Steatohepatitis, Nonalcoholic
The COherence of Scatter Identification and Exclusion Algorithm Study
Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver condition worldwide; approximately 55% of the world population will have NAFLD by 2040.
- Trial name
- COSIE (NCT06975579)
- Testing
- Ultrasound image processing
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Institute of Cancer Research, United Kingdom
Non-Alcoholic Fatty Liver Disease
Tocotrienol as a Treatment for Non-alcoholic Fatty Liver Disease
Vitamin E's potential in treating non-alcoholic fatty liver disease (NAFLD) is attributed to its antioxidant properties. While tocopherols have shown significant results in NAFLD management, the powerful properties of…
- Trial name
- NCT06596382
- Testing
- Tocotrienol rich-vitamin E
- Where
- Malaysia
- Volunteers
- 264 people
- Sponsor
- National University of Malaysia
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Non-Alcoholic Fatty Liver Disease in a Saudi Cohort With Type 2 Diabetes Mellitus
The global rise in the prevalence of obesity paved the way for the increased prevalence of yet another obesity-related complication significant enough to be considered within the roster of major public health threats…
- Trial name
- CORDIAL (NCT05697991)
- Where
- Saudi Arabia
- Volunteers
- 1,000 people
- Sponsor
- King Saud University
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD.
The primary objective of this study is to assess the clinical performance of LIVERFAStTM In Vitro Diagnostic (IVD) Tests (Fibrosis score, Activity score and Steatosis score) in NAFLD suspected patients for staging of fibrosis and…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Liver Fibroses, Liver Inflammation
- Trial name
- NCT04579874
- Testing
- LIVERFASt
- Where
- 8 sites in United States
- Volunteers
- 241 people
- Sponsor
- Fibronostics USA, Inc
Non-Alcoholic Fatty Liver Disease
Gemcabene for the Treatment of Pediatric NAFLD
This is a multicenter, prospective, open-label, Phase 2, proof of concept study to test preliminary efficacy and safety of gemcabene in children with established nonalcoholic fatty liver disease (NAFLD) incompletely treated by…
- Trial name
- NCT03436420
- Testing
- Gemcabene
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Emory University
Non - Alcoholic Steatohepatitis
A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects
The safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics study of HEC169584 capsules in healthy subjects .
- Trial name
- NCT07099118
- Testing
- HEC169584 capsule
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Non-alcoholic Fatty Liver Disease
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.
- Trial name
- ZENITH-2 (NCT07221188)
- Testing
- Efimosfermin Alfa
- Where
- 66 sites in United States, Australia and 6 more
- Volunteers
- 1,250 people
- Sponsor
- GlaxoSmithKline
Metabolic Associated Fatty Liver Disease, Bariatric Surgery Candidate
Short Term Outcome of Metabolic Associated Fatty Liver Disease (MAFLD) in Patients Undergoing Bariatric Surgery
Obesity has become one of the most critical public health problems in economically developed and developing countries in the world.
- Trial name
- NCT06180928
- Volunteers
- 50 people
- Sponsor
- Assiut University
Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease.
- Conditions
- Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis
- Trial name
- TESA-LIVER (NCT07481734)
- Testing
- Tesamorelin, Standardized lifestyle counseling
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Hudson Biotech
Nash
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients
Human genetic studies have shown that loss of function (LOF) mutations in HSD17β13 gene have a protective effect on the progression of alcohol-related and non-alcohol-related liver diseases, such as NASH, without significant…
- Trial name
- NCT06322628
- Testing
- VSA006
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Visirna Therapeutics HK Limited
Liver Disease, Fatty Liver
Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Background: Metabolism refers to the many chemical pathways by which various compounds, including food, are processed and used in the body.
- Trial name
- NCT02520609
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non Alcoholic Fatty Liver Disease, Obstructive Sleep Apnea
The Sleep, Liver Evaluation and Effective Pressure Study
This research is being done to examine: 1) how common obstructive sleep apnea (OSA) is in patients with non-alcoholic fatty liver disease (NAFLD), 2) whether the severity of OSA is related to the severity of NAFLD, and 3) whether…
- Trial name
- SLEEP (NCT01482065)
- Testing
- CPAP (ResMed S9 autoset CPAP)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University
Nonalcoholic Fatty Liver Disease (NAFLD)
Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD
The purpose of this research is to gather information on the combination Zetia® (Ezetimibe) and Urso Forte® with respect to sterol balance and their effects on biomarkers of liver function in subjects with nonalcoholic fatty…
- Trial name
- NCT02244944
- Testing
- EZ-Urso combination therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Gregory Graf, PhD
Non-Alcoholic Fatty Liver Disease
A Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects.
Aimed at evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of XTYW007 in healthy subjects and healthy subjects with elevated LDL-C, as well as studying the effects of food on…
- Trial name
- NCT07407634
- Where
- China
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Nonalcoholic Steatohepatitis
Non Alcoholic Fatty Liver Disease and Coronary Heart Disease in Type 2 Diabetes Patients
To assess the feasibility in diabetics in a primary care setting of screening for NAFLD and advanced fibrosis, by using non-invasive magnetic resonance imaging (MRI) to estimate the hepatic proton density fat fraction (MRI-PDFF)…
- Trial name
- NCT04462081
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, San Diego
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.